Therapeutic strategies aimed at fine-tuning PTH delivery (e.g., pulsatile analogs) or modulating PTH-induced content may open new avenues for treating age-related musculoskeletal and NMJ degeneration, particularly in conditions like osteosarcopenia or sarcopenic neurodegeneration. The gene discussed is PTH; the disease is age.